RU2015134357A - Пептид - Google Patents
Пептид Download PDFInfo
- Publication number
- RU2015134357A RU2015134357A RU2015134357A RU2015134357A RU2015134357A RU 2015134357 A RU2015134357 A RU 2015134357A RU 2015134357 A RU2015134357 A RU 2015134357A RU 2015134357 A RU2015134357 A RU 2015134357A RU 2015134357 A RU2015134357 A RU 2015134357A
- Authority
- RU
- Russia
- Prior art keywords
- plp
- seq
- peptide according
- disease
- peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rehabilitation Therapy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Marine Sciences & Fisheries (AREA)
Claims (28)
1. Пептид, способный связываться с молекулой МНС in vitro и быть представленным Т-клетке без процессинга антигена, который содержит все или часть следующих пептидов протеолипидного белка (PLP):
PLP 36-61: HEALTGTEKLIETYFSKNYQDYEYLI (SEQ ID NO. 1);
PLP 179-206: TWTTCQSIAFPSKTSASIGSLCADARMY (SEQ ID NO. 2);
PLP 207-234: GVLPWNAFPGKVCGSNLLSICKTAEFQM (SEQ ID NO. 3).
2. Пептид по п. 1, содержащий часть следующих пептидов:
PLP 39-57: LTGTEKLIETYFSKNYQDY (SEQ ID NO. 4);
PLP 180-198: WTTCQSIAFPSKTSASIGS (SEQ ID NO. 5);
PLP 208-222: VLPWNAFPGKVCGSN (SEQ ID NO. 6).
3. Пептид по п. 1, который выбран из следующих пептидов PLP:
PLP 39-53: LTGTEKLIETYFSKN (SEQ ID NO. 7);
PLP 42-56: TEKLIETYFSKNYQD (SEQ ID NO. 8);
PLP 43-57: EKLIETYFSKNYQDY (SEQ ID NO. 9);
PLP 180-194: WTTCQSIAFPSKTSA (SEQ ID NO. 10);
PLP 181-195: TTCQSIAFPSKTSAS (SEQ ID NO. 11);
PLP 182-196: TCQSIAFPSKTSASI (SEQ ID NO. 12);
PLP 183-197: CQSIAFPSKTSASIG (SEQ ID NO. 13);
PLP 184-198: QSIAFPSKTSASIGS (SEQ ID NO. 14);
PLP 208-222: VLPWNAFPGKVCGSN (SEQ ID NO. 15);
PLP 36-61: HEALTGTEKLIETYFSKNYQDYEYLI (SEQ ID NO. 1);
PLP 179-206: TWTTCQSIAFPSKTSASIGSLCADARMY (SEQ ID NO. 2) и
PLP 207-234: GVLPWNAFPGKVCGSNLLSICKTAEFQM (SEQ ID NO. 3).
4. Пептид по любому из предшествующих пунктов для использования в лечении и/или профилактике демиелинизирующего заболевания.
5. Пептид по п. 4, где заболевание представляет собой рассеянный склероз.
6. Фармацевтическая композиция, содержащая один или более пептидов по любому из пп. 1-5.
7. Способ лечения и/или профилактики демиелинизирующего заболевания у субъекта, который нуждается в этом, включающий этап введения пептида по любому из пп. 1-5 субъекту.
8. Способ по п. 7, где заболевание представляет собой рассеянный склероз.
9. Применение пептида по любому из пп. 1-5 в производстве лекарственного средства, предназначенного для профилактики и/или лечения демиелинизирующего заболевания.
10. Применение по п. 9, где заболевание представляет собой рассеянный склероз.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1300683.8A GB201300683D0 (en) | 2013-01-15 | 2013-01-15 | Peptide |
| GB1300683.8 | 2013-01-15 | ||
| PCT/IB2014/058234 WO2014111841A2 (en) | 2013-01-15 | 2014-01-13 | Peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015134357A true RU2015134357A (ru) | 2017-02-22 |
| RU2667428C2 RU2667428C2 (ru) | 2018-09-19 |
Family
ID=47757994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015134357A RU2667428C2 (ru) | 2013-01-15 | 2014-01-13 | Пептид |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20150352197A1 (ru) |
| EP (1) | EP2945965B8 (ru) |
| JP (2) | JP6407888B2 (ru) |
| KR (1) | KR102129763B1 (ru) |
| CN (1) | CN105102477B (ru) |
| AU (1) | AU2014206593B2 (ru) |
| CA (2) | CA3154542A1 (ru) |
| DK (1) | DK2945965T3 (ru) |
| ES (1) | ES2694660T3 (ru) |
| GB (1) | GB201300683D0 (ru) |
| HK (1) | HK1211595A1 (ru) |
| HU (1) | HUE040547T2 (ru) |
| IL (1) | IL239870B (ru) |
| MX (1) | MX369413B (ru) |
| PL (1) | PL2945965T3 (ru) |
| PT (1) | PT2945965T (ru) |
| RU (1) | RU2667428C2 (ru) |
| SG (1) | SG11201505530XA (ru) |
| TR (1) | TR201815667T4 (ru) |
| WO (1) | WO2014111841A2 (ru) |
| ZA (1) | ZA201504986B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3668535A1 (en) * | 2017-08-14 | 2020-06-24 | Apitope Technology (Bristol) Limited | Method |
| WO2021144478A2 (en) | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
| KR20240015672A (ko) | 2021-06-01 | 2024-02-05 | 임시스 에스에이 | 면역원성 펩티드를 사용한 개선된 치료 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| WO2003040165A2 (en) * | 2000-10-19 | 2003-05-15 | Epimmune Inc. | Hla class i and ii binding peptides and their uses |
| US9340577B2 (en) * | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| EP0825870A4 (en) * | 1995-04-20 | 2002-09-25 | Brigham & Womens Hospital | MODULATION OF CYTOKINIC SEQUENCES OF SELF-REACTIVE T HUMAN CELL CLONES |
| AU5671196A (en) * | 1996-03-28 | 1997-10-17 | Immulogic Pharmaceutical Corporation | Myelin oligodendrocyte glycoprotein peptides and uses thereof |
| IL146016A0 (en) * | 2001-10-17 | 2002-07-25 | Yeda Res & Dev | Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis |
| RU2387453C2 (ru) * | 2004-06-25 | 2010-04-27 | АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК | Композиции и способы лечения неврологических нарушений |
| US8188218B2 (en) * | 2006-10-27 | 2012-05-29 | University Of Kansas | Bi-functional peptides for multiple sclerosis treatment and diagnosis |
| US20120076808A1 (en) * | 2010-09-27 | 2012-03-29 | China Agricultural University | Combined antigen and dna vaccine for preventing and treating autoimmune diseases |
-
2013
- 2013-01-15 GB GBGB1300683.8A patent/GB201300683D0/en not_active Ceased
-
2014
- 2014-01-13 WO PCT/IB2014/058234 patent/WO2014111841A2/en active Application Filing
- 2014-01-13 JP JP2015552189A patent/JP6407888B2/ja active Active
- 2014-01-13 CA CA3154542A patent/CA3154542A1/en active Pending
- 2014-01-13 HU HUE14703176A patent/HUE040547T2/hu unknown
- 2014-01-13 CN CN201480009124.4A patent/CN105102477B/zh active Active
- 2014-01-13 ES ES14703176.9T patent/ES2694660T3/es active Active
- 2014-01-13 KR KR1020157020498A patent/KR102129763B1/ko active IP Right Grant
- 2014-01-13 US US14/760,492 patent/US20150352197A1/en not_active Abandoned
- 2014-01-13 MX MX2015009086A patent/MX369413B/es active IP Right Grant
- 2014-01-13 RU RU2015134357A patent/RU2667428C2/ru active
- 2014-01-13 CA CA2897894A patent/CA2897894C/en active Active
- 2014-01-13 EP EP14703176.9A patent/EP2945965B8/en active Active
- 2014-01-13 PL PL14703176T patent/PL2945965T3/pl unknown
- 2014-01-13 PT PT14703176T patent/PT2945965T/pt unknown
- 2014-01-13 SG SG11201505530XA patent/SG11201505530XA/en unknown
- 2014-01-13 DK DK14703176.9T patent/DK2945965T3/en active
- 2014-01-13 TR TR2018/15667T patent/TR201815667T4/tr unknown
- 2014-01-13 AU AU2014206593A patent/AU2014206593B2/en active Active
-
2015
- 2015-07-09 IL IL239870A patent/IL239870B/en active IP Right Grant
- 2015-07-10 ZA ZA2015/04986A patent/ZA201504986B/en unknown
- 2015-12-11 HK HK15112228.2A patent/HK1211595A1/xx unknown
-
2018
- 2018-07-27 JP JP2018141119A patent/JP2018193390A/ja not_active Withdrawn
-
2019
- 2019-03-26 US US16/365,365 patent/US20190275126A1/en not_active Abandoned
-
2021
- 2021-03-01 US US17/188,318 patent/US20220016226A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| EA201690738A1 (ru) | Ингалятор сухого порошка | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| IN2014KN01715A (ru) | ||
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2015518818A5 (ru) | ||
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| MX2019012884A (es) | Terapia de combinacion. | |
| SG11202005772YA (en) | Mhc class i associated peptides for prevention and treatment of multiple flavi virus | |
| JP2011528897A5 (ru) | ||
| EA201391387A1 (ru) | Нейропротекторные пептиды | |
| EA201791632A1 (ru) | Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат | |
| EA201791537A1 (ru) | Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение | |
| RU2015134357A (ru) | Пептид | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| RU2014102941A (ru) | Вакцинная композиция для введения через слизистую оболочку | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| EA202190429A1 (ru) | Биодоступные пероральные дозированные формы | |
| RU2015134356A (ru) | Пептид |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |